4/A//SEC Filing
Gelbfish Gary A. 4/A
Accession 0001654954-18-013410
CIK 0001410098other
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 4:12 PM ET
Size
17.5 KB
Accession
0001654954-18-013410
Insider Transaction Report
Form 4/AAmended
CorMedix Inc.CRMD
Gelbfish Gary A.
Director
Transactions
- Tax Payment
Common Stock
2018-10-12$2.24/sh−468,750$1,050,000→ 2,642,371 total - Exercise/Conversion
Series B Common Stock Warrant
2018-10-12−1,000,000→ 0 totalExercise: $1.05→ Common Stock, $0.001 par value per share (1,000,000 underlying) - Other
Series A Common Stock Warrant
2018-09-10−1,000,000→ 0 totalExercise: $0.75→ Common Stock, $0.001 par value per share (1,000,000 underlying) - Exercise/Conversion
Common Stock
2018-10-12$1.05/sh+1,000,000$1,050,000→ 3,111,121 total
Holdings
- 14,000(indirect: By Foundation)
Common Stock
- 40,000
Stock Option (Right to Buy Common Stock)
Exercise: $0.57Exp: 2028-02-16→ Common Stock, $0.001 par value per share (40,000 underlying) - 75,000
Stock Option (Right to Buy Common Stock)
Exercise: $0.37Exp: 2027-08-03→ Common Stock, $0.001 par value per share (75,000 underlying) - 500,000
Series C-3 Non-Voting Convertible Preferred Stock
From: 2014-01-08→ Common Stock, $0.001 par value per share (500,000 underlying) - 250,000
Warrant (Right to Purchase Common Stock)
Exercise: $0.90From: 2015-01-08Exp: 2020-01-08→ Common Stock, $0.001 par value per share (250,000 underlying)
Footnotes (7)
- [F1]This amendment is being filed solely to correct the reporting person's holdings to reflect an ownership correction to a report filed on 2/20/2018 and amended the same date as this amended report.
- [F2]Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
- [F3]The Series B Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of five years from the Initial Exercise Date.
- [F4]The Series A Common Stock warrant is exercisable any time after the Company publicly announces through the filing of a Current Report on Form 8-K that the Company has received Stockholder Approval and the amendment to the Company's Certificate of Incorporation has become effective (the "Initial Exercise Date"). The warrant shall be exercisable for a period of thirteen months from the Initial Exercise Date.
- [F5]These options were granted on 2/16/2018. The options vest in full on the first anniversary of the date of grant, subject to continued service on the board.
- [F6]These options vest as follows: 1/3 on August 3, 2017, an additional 1/3 on August 3, 2018, and the remaining 1/3 on August 3, 2019.
- [F7]The conversion ratio is equal to the stated value of $10.00 divided by the conversion price of $1.00. The Series C-3 Non-Voting Convertible Preferred Stock is perpetual.
Documents
Issuer
CorMedix Inc.
CIK 0001410098
Entity typeother
Related Parties
1- filerCIK 0001488011
Filing Metadata
- Form type
- 4/A
- Filed
- Nov 29, 7:00 PM ET
- Accepted
- Nov 30, 4:12 PM ET
- Size
- 17.5 KB